11/14
07:39 am
lyra
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
04:12 pm
lyra
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
lyra
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High
Report
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/15
07:00 am
lyra
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Low
Report
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
9/27
07:00 am
lyra
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Medium
Report
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
9/6
06:59 am
lyra
Lyra Therapeutics, Inc. (NASDAQ: LYRA) was upgraded by analysts at William Blair to a "hold" rating.
Medium
Report
Lyra Therapeutics, Inc. (NASDAQ: LYRA) was upgraded by analysts at William Blair to a "hold" rating.